---
# === IDENTIFICATION ===
id: aha-heart-failure-2022
title: "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure"
short_title: "AHA Heart Failure 2022"

# === SOURCE ===
organization: American Heart Association
collaborators:
  - American College of Cardiology
  - Heart Failure Society of America
country: US
url: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063
doi: 10.1161/CIR.0000000000001063
pmid: 35363499
open_access: true

# === CLASSIFICATION ===
specialty: cardiology
guideline_type: clinical-practice
evidence_system: AHA
conditions:
  - heart failure
  - cardiomyopathy
  - HFrEF
  - HFpEF
  - HFmrEF
tags:
  - GDMT
  - SGLT2 inhibitors
  - ARNI
  - beta blockers
  - MRA
  - ICD
  - CRT

# === VERSIONING ===
publication_date: 2022-04-01
previous_version_date: 2017-04-28
status: current
supersedes: aha-heart-failure-2017
superseded_by: null

# === LOCAL TRACKING ===
pdf_path: null
has_pdf: false
last_reviewed: 2025-12-21
---

## Scope

Comprehensive guideline for diagnosis, staging, and management of heart failure across all ejection fraction phenotypes (HFrEF, HFmrEF, HFpEF) in adults.

## Notes

Major update introducing the new universal definition of HF and updated staging system. Key changes include:
- Expanded GDMT to "quadruple therapy" for HFrEF (ARNI/ACEi/ARB + beta-blocker + MRA + SGLT2i)
- SGLT2 inhibitors now Class I recommendation for HFrEF and HFpEF
- New HFmrEF category (EF 41-49%) with specific recommendations
